Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v3.5.0.2
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Statement [Abstract]        
Sales (Note 1) $ 1,923 $ 57,089 $ 1,923 $ 92,894
Cost of sales 1,567 14,533 1,567 26,636
Gross profit 356 42,556 356 66,258
Other revenue - fee (Note 8) 24,175 24,175 72,524 72,524
Operating expenses:        
Selling, general and administrative 1,715,475 1,231,101 3,568,436 4,249,560
Research and development 54,458 426,263 500,129 1,686,413
Total operating expenses 1,769,933 1,657,364 4,068,565 5,935,973
Operating loss (1,745,402) (1,590,633) (3,995,685) (5,797,191)
Other income (expense):        
Gain on sale of property and equipment (Note 3) 13,062 1,933,335
Interest expense (2,384) (25,393) (28,130) (74,652)
Investment income 23,639 32,942 103,031 69,151
Total other income (expense) 34,317 7,549 2,008,236 (5,501)
Net loss (1,711,085) (1,583,084) (1,987,449) (5,802,692)
Net loss attributable to non-controlling interest 1,153 1,153
Net loss attributable to Venaxis, Inc. $ (1,709,932) $ (1,583,084) $ (1,986,296) $ (5,802,692)
Basic and diluted net loss per share (Note 1) $ (0.43) $ (0.41) $ (0.51) $ (1.50)
Basic and diluted weighted average number of shares outstanding (Note 1) 3,999,637 3,876,961 3,918,151 3,876,961